Fibrosis is an irreversible pathological process affecting multiple organs, primarily involving the extracellular matrix components like collagen, fibronectin (FN), and α-smooth muscle actin (α-SMA). While it's a crucial stage in organ tissue repair, severe repetitive injuries can trigger activation of local tissue fibroblasts. This activation enhances contractility, inflammatory mediator secretion, and ECM component accumulation. Consequently, this leads to tissue structure deterioration, organ dysfunction, and eventual failure, contributing significantly to heightened morbidity and mortality across various diseases.
Figure 1. Common characteristics of organ fibrosis. Injurious events lead to organ damage, inflammation, and fibrosis in liver, kidney, lung, heart, and skin. [1]
Creative Bioarray has significant expertise in drug discovery in the field of fibrosis. In addition to a series of validated cellular models of fibrosis using liver, lung, kidney, and other fibroblasts, our biological scientists are also adept at developing customized assays for individual projects to meet customers' drug discovery needs.
Reference:
1. Weiskirchen, Ralf et al. "Organ and tissue fibrosis: Molecular signals, cellular mechanisms and translational implications." Molecular aspects of medicine vol. 65 (2019): 2-15. doi:10.1016/j.mam.2018.06.003
Online Inquiry
